Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?
- PMID: 26051165
- PMCID: PMC4458515
- DOI: 10.7448/IAS.18.1.19933
Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?
Abstract
Background: The risk of pre-term birth (PTB) associated with the use of protease inhibitors (PIs) during pregnancy remains a subject of debate. Recent data suggest that ritonavir boosting of PIs may play a specific role in the initiation of PTB, through an effect on the maternal-fetal adrenal axis. The primary objective of this study is to compare the risk of PTB among women treated with boosted PI versus non-boosted PIs during pregnancy.
Methods: Between 1988 and 2011, 705 HIV-positive women were enrolled into the Centre Maternel et Infantile sur le SIDA mother-infant cohort at Centre Hospitalier Universitaire Sainte-Justine in Montreal, Canada. Inclusion criteria for the study were: 1) attendance at a minimum of two antenatal obstetric visits and 2) singleton live birth, at 24 weeks gestational or older. The association between PTB (defined as delivery at <37 weeks gestational age), antiretroviral drug exposure and maternal risk factors was assessed retrospectively using logistic regression.
Results: A total of 525 mother-infant pairs were included in the analysis. Among them, PI-based combination anti-retroviral therapy was used in 37.4%, boosted PI based in 24.4%, non-nucleoside reverse transcriptase inhibitor (NNRTI) or nucleoside reverse transcriptase inhibitor based in 28.1%, and no treatment was given in 10.0% of cases. Overall, 13.5% of women experienced PTB. Among women treated with antiretroviral therapy, the risk of PTB was significantly higher among women who received boosted versus non-boosted PI (OR 2.01, 95% CI 1.02-3.97). This remained significant after adjusting for maternal age, delivery CD4 count, hepatitis C co-infection, history of previous PTB, and parity (aOR 2.17, 95% CI 1.05-4.51). There was no increased risk of PTB with the use of unboosted PIs as compared to NNRTI- or NRTI-based regimens.
Conclusion: While previous studies on the association between PTB and PI use have generally considered all PIs the same, our results would indicate a possible role of ritonavir boosting as a risk factor for PTB. Further work is needed to understand the pathophysiologic mechanisms involved, and to identify the safest ARV regimens to be used in pregnancy.
Keywords: HIV transmission; antiretroviral drugs; mother-to-child prevention; pre-term birth; protease inhibitors.
Similar articles
-
Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis.BMC Pregnancy Childbirth. 2023 Jan 30;23(1):80. doi: 10.1186/s12884-023-05347-5. BMC Pregnancy Childbirth. 2023. PMID: 36717801 Free PMC article.
-
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.AIDS. 2019 Dec 1;33(15):2403-2413. doi: 10.1097/QAD.0000000000002367. AIDS. 2019. PMID: 31764105 Free PMC article. Clinical Trial.
-
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Cochrane Database Syst Rev. 2013. PMID: 23740608 Review.
-
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD005481. doi: 10.1002/14651858.CD005481.pub3. Cochrane Database Syst Rev. 2013. PMID: 23543540 Free PMC article. Review.
-
Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?Clin Infect Dis. 2012 May;54(9):1348-60. doi: 10.1093/cid/cis198. Epub 2012 Mar 28. Clin Infect Dis. 2012. PMID: 22460969
Cited by
-
Antiretroviral Therapy Use Was Not Associated with Stillbirth or Preterm Birth in an Analysis of U.S. Medicaid Pregnancies to Persons with HIV.Womens Health Rep (New Rochelle). 2023 Aug 25;4(1):438-447. doi: 10.1089/whr.2023.0040. eCollection 2023. Womens Health Rep (New Rochelle). 2023. PMID: 37638332 Free PMC article.
-
Adverse pregnancy outcomes associated with antiretroviral therapy initiated before pregnancy and during pregnancy: a retrospective study in Hubei province, China.Front Med (Lausanne). 2023 May 18;10:1158962. doi: 10.3389/fmed.2023.1158962. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37275371 Free PMC article.
-
Adverse perinatal outcomes associated with antiretroviral therapy in women living with HIV: A systematic review and meta-analysis.Front Med (Lausanne). 2023 Feb 3;9:924593. doi: 10.3389/fmed.2022.924593. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36816720 Free PMC article.
-
Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines-A Scoping Review.Vaccines (Basel). 2023 Jan 1;11(1):107. doi: 10.3390/vaccines11010107. Vaccines (Basel). 2023. PMID: 36679952 Free PMC article. Review.
-
Iron, folic acid, and multiple micronutrient supplementation strategies during pregnancy and adverse birth outcomes in Botswana.Lancet Glob Health. 2022 Jun;10(6):e850-e861. doi: 10.1016/S2214-109X(22)00126-7. Lancet Glob Health. 2022. PMID: 35561720 Free PMC article.
References
-
- European Collaborative Study; Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14(18):2913–20. - PubMed
-
- Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18(17):2337–9. - PubMed
-
- Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21(8):1019–26. - PubMed
-
- Grosch-Woerner I, Puch K, Maier RF, Niehues T, Notheis G, Patel D, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med. 2008;9(1):6–13. - PubMed
-
- Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38(4):449–73. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous